Sol-Gel Technologies Ltd. (NASDAQ: SLGL)

Sol-Gel Technologies Ltd. is an innovative dermatology company focused on developing and commercializing advanced topical treatments for severe skin conditions. The company leverages proprietary silica-based microencapsulation technology to create therapies that address unmet medical needs in dermatology, particularly for rare and chronic skin disorders. Sol-Gel’s portfolio includes two U. S. Food and Drug Administration (FDA)-approved products, Twyneo and Epsolay, alongside a robust pipeline of drug candidates targeting orphan indications, such as Gorlin syndrome and high-frequency basal cell carcinoma (BCC).

The company generates revenue primarily through licensing agreements, milestone payments, and royalties from commercial partners. Twyneo, a once-daily topical cream for acne vulgaris, and Epsolay, a treatment for inflammatory lesions of rosacea, were previously marketed in the U. S. by Galderma before Sol-Gel sold its U. S. rights to Mayne Pharma in April 2025. The company also earns revenue from exclusive licensing deals in Canada, China, Europe, and other regions, where partners handle regulatory and commercial activities. Additionally, Sol-Gel receives payments from collaborations on generic drug development, including quarterly fees and royalties from Padagis for a generic version of Zoryve Cream.

The company operates through the following segments:

• Approved Products: This segment includes Twyneo and Epsolay, both of which have received FDA approval. Twyneo is a fixed-dose combination of encapsulated benzoyl peroxide and tretinoin for acne vulgaris, while Epsolay contains encapsulated benzoyl peroxide for inflammatory lesions of rosacea. These products are commercialized through partnerships with companies like Mayne Pharma, Searchlight Pharma, and Beimei Pharmaceutical, which handle marketing, sales, and distribution in their respective territories.

• Pipeline Candidates: This segment focuses on the development of SGT-610 (patidegib gel 2%) and SGT-210, both of which target rare dermatological conditions. SGT-610 is in Phase 3 clinical trials for the prevention of new BCCs in Gorlin syndrome patients and is also being evaluated for high-frequency BCC. SGT-210, a topical epidermal growth factor receptor inhibitor, is being explored for new indications with significant unmet needs, such as Olmsted syndrome. The company holds orphan drug and breakthrough therapy designations for SGT-610, which could expedite its regulatory pathway.

• Generic Drug Development: Sol-Gel collaborates with partners like Padagis to develop generic topical dermatological products. This segment includes the development of a generic version of Zoryve Cream (roflumilast cream 0.3%), for which the company receives quarterly payments and royalties. The company previously sold rights to 10 generic programs to Padagis, retaining only the Zoryve collaboration.

Sol-Gel Technologies Ltd. occupies a unique position in the dermatology market, particularly in the niche of rare and severe skin conditions. The company’s competitive advantage lies in its proprietary silica-based microencapsulation technology, which enhances drug stability, tolerability, and efficacy. This technology enables the development of fixed-dose combinations and topical formulations that minimize systemic side effects, a key differentiator in the dermatology space. Key competitors include companies like Galderma, Mayne Pharma, and Almirall, which market branded and generic dermatological products. Sol-Gel’s focus on orphan indications, such as Gorlin syndrome, sets it apart from larger players that prioritize broader markets. The company’s pipeline candidates, particularly SGT-610, have the potential to address significant unmet needs, with peak annual net sales estimates exceeding $600 million for the Gorlin syndrome indication alone.

The company’s customer base primarily consists of dermatologists, patients with severe skin conditions, and commercial partners. Twyneo and Epsolay target patients suffering from acne vulgaris and rosacea, respectively, while SGT-610 is aimed at individuals with Gorlin syndrome or high-frequency BCC. Sol-Gel’s products are distributed through partnerships with companies such as Mayne Pharma (U. S.), Searchlight Pharma (Canada), Beimei Pharmaceutical (China, Hong Kong, Macau, Taiwan, and Israel), and Viatris (Australia and New Zealand). These partners handle the commercialization and marketing of Sol-Gel’s products, ensuring broad reach to healthcare providers and patients in their respective regions.